Juan C. Osorio MD
juanosoriomd.bsky.social
Juan C. Osorio MD
@juanosoriomd.bsky.social
Assist Attending & Medical oncologist MSKCC & Rockefeller University | Antibody biology | Cancer immunology | GMO, GU | @MSK, @WeillCornellMed @BWH @UNAL | 🇨🇴🏳️‍🌈

https://www.mskcc.org/research-areas/labs/juan-osorio
Reposted by Juan C. Osorio MD
An agonist anti-CD40 with enhanced binding to FcγRIIB showed early promise in a small cohort of patients with metastatic melanoma. Read our digest here 👉 bit.ly/4nc91nR  @juanosoriomd.bsky.social‬  @mskcancercenter.bsky.social
August 20, 2025 at 3:30 PM
Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work at the Ravetch lab led to this moment, made possible by an amazing team! 🧵 🪡 www.cell.com/cancer-cell/...
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer
Osorio et al. report a first-in-human study of intratumoral 2141-V11, an Fc-engineered CD40 agonistic antibody, showing it is safe and induces systemic and durable antitumor immunity in patients with ...
www.cell.com
August 15, 2025 at 1:45 PM
Reposted by Juan C. Osorio MD
Anti-CD47/CD40 antibodies are emerging as new IO treatment options! Explore recent updates on these antibodies with an expert presentation from a former SITC abstract presenter
@juanosoriomd.bsky.social at the 29th JACI Annual Meeting July 24-26 in Japan or virtual: ow.ly/O36B50W0cVS 🧪

#OncSky
July 7, 2025 at 3:57 PM
Join us at #CICON25, September 10-12 in Utrecht. This is an exciting venue to explore how novel insights in immuno-oncology can translate into life-changing outcomes! Review the program, submit an abstract and register today: bit.ly/4cjiDJ4 cancerimmunotherapyconference.org
May 23, 2025 at 10:41 PM
Reposted by Juan C. Osorio MD
Biologics and T-cell Engagers: Researchers shared updates on cutting-edge immunotherapies during this #AACR25 Clinical Trials Plenary Session. Read a recap in AACR Annual Meeting News: www.aacrmeetingnews.org/news/cutting... @juanosoriomd.bsky.social
May 14, 2025 at 10:11 PM
Excited for tomorrow! 👇 #AACR25
Thrilled to present at @theaacr.bsky.social annual meeting at the Clinical Trials Plenary Session on Biologics and T-cell Engagers! See you there to present some exciting data on our Fc-engineered CD40 agonistic antibody #AACR25
April 28, 2025 at 8:42 PM
Interested in assessing antibody-dependent cellular phagocytosis by primary macrophages? Here is a practical and optimized protocol developed by dedicated and talented members of the lab, enjoy!

www.sciencedirect.com/science/arti...
Protocol for assessing antibody-dependent cellular phagocytosis by primary murine and human macrophages
Macrophages play a crucial role in mediating antibody-dependent cellular phagocytosis (ADCP), a process that enhances the effectiveness of several can…
www.sciencedirect.com
April 24, 2025 at 9:28 PM
Interested in myeloid cell anti-tumor immunity? I’ll be presenting at the NIH/NCI Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity urldefense.com/v3/__https:/...
Cassyni | Science starts with a seminar
Seamlessly organise, run and publish academic research seminars. Get started in minutes.
urldefense.com
April 14, 2025 at 3:25 PM
Thrilled to present at @theaacr.bsky.social annual meeting at the Clinical Trials Plenary Session on Biologics and T-cell Engagers! See you there to present some exciting data on our Fc-engineered CD40 agonistic antibody #AACR25
March 31, 2025 at 11:33 AM
Reposted by Juan C. Osorio MD
Betty Kim & Wen Jiang and colleagues report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.
@bettykimmdphd.bsky.social @wenjiang-nano.bsky.social @mdanderson.bsky.social
⬇️
www.nature.com/articles/s43...
An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy - Nature Cancer
Schrank et al. report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.
www.nature.com
March 22, 2025 at 10:07 AM
Curious if people are starting to receive NOAs more recently? Whether any signs of normalcy or whether the waiting still continues? Are these categories 1-4 now in action?
March 11, 2025 at 1:14 AM
Science not silence
March 7, 2025 at 6:59 PM
So needed at this moment
These are extremely challenging times for early-career faculty. Here is my office's small contribution to make their hard and important work a bit easier:

Download our curated and comprehensive database of funding opportunities for early-career faculty.

Here: research.jhu.edu/rdt/funding-...
March 7, 2025 at 12:42 AM
Reposted by Juan C. Osorio MD
1. UPDATE

The NIH is still blocking most ongoing scientific funding over concerns about DEI, according to NIH sources and internal NIH correspondence.

The freeze has continued even after top NIH officials acknowledged that continuing to block the funding would violate a federal court order.
UPDATE: NIH reimposes "DEI" funding freeze despite court order
The National Institutes of Health (NIH) is still blocking most ongoing scientific funding over concerns about "diversity, equity and inclusion" (DEI), according to NIH sources and internal NIH corresp...
popular.info
February 24, 2025 at 1:43 PM
Reposted by Juan C. Osorio MD
🎥 @juanosoriomd.bsky.social discusses a Phase I study on 2141-V11, an anti-CD40 antibody designed to enhance FcγRIIB binding, aiming to improve tumor response & reduce toxicity:

➡️ https://buff.ly/3BCEtJL ⬅️

@sitcancer.bsky.social #SITC24 #Immunotherapy
2141-V11: an anti-CD40 monoclonal antibody for tumor regression in patients with metastatic cancer - VJOncology
Juan Osorio, MD, Memorial Sloan Kettering Cancer Center, The Rockefeller University, New York, NY, introduces an in-human Phase I study...
buff.ly
January 2, 2025 at 3:54 PM
Thrilled to present our for on this co-“stimulating” session organized by @sitcancer.bsky.social Join us this Thursday! Moderated by leaders in the field and presentations of exciting progress in IO for cancer. sitcancer.org/education/we...
December 9, 2024 at 2:41 PM
Taking a deep breath, hoping this is a brighter sky
November 13, 2024 at 2:04 AM